Tidemark’s iShares Biotechnology ETF IBB Stock Holding History

Tidemark’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-95	Closed	-$12.2K	–	724
2025 Q1	$12.2K	Hold	95	–	–	﹤0.01%	410
2024 Q4	$12.6K	Hold	95	–	–	﹤0.01%	408
2024 Q3	$13.8K	Hold	95	–	–	0.01%	394
2024 Q2	$13K	Sell	95 -30	-24%	-$4K	0.01%	379
2024 Q1	$17.2K	Hold	125	–	–	0.01%	359
2023 Q4	$17K	Buy	+125	New	+$15.3K	0.01%	352

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Tidemark's IBB Position: Q2 2025 in Review

Tidemark sold out of iShares Biotechnology ETF (IBB) in Q2 2025, closing a stake of 95 shares — an estimated $12.2K sold.

Tidemark first reported a position in IBB in Q4 2023 and held it in 6 quarters. The position peaked at $17.2K in Q1 2024. 797 funds tracked by Wall St. Rank hold IBB as of Q2 2025.

Tidemark reported no remaining iShares Biotechnology ETF position as of Q2 2025 after selling out during the quarter.
Tidemark sold 95 iShares Biotechnology ETF shares in Q2 2025, an estimated $12.2K.
Tidemark first reported a position in iShares Biotechnology ETF in Q4 2023 and held it in 6 quarters.
Tidemark's iShares Biotechnology ETF position peaked at $17.2K in Q1 2024.
797 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2025.

Based on Tidemark's 13F filing for Q2 2025, filed 11 Aug 2025.